Pembrolizumab receives accelerated approval from the FDA for HER2-positive gastric cancer

Share This Post

August 2021: Pembrolizumab (Keytruda, Merck & Co.) in combination with trastuzumab, fluoropyrimidine-, and platinum-containing chemotherapy has been granted accelerated approval by the Food and Drug Administration for the first-line treatment of patients with locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.

The KEYNOTE-811 (NCT03615326) trial, a multicenter, randomised, double-blind, placebo-controlled trial in patients with HER2 positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who had not previously received systemic therapy for metastatic disease, received approval based on a prespecified interim analysis of the first 264 patients. Pembrolizumab 200 mg or placebo was given to patients every three weeks in conjunction with trastuzumab and either fluorouracil plus cisplatin or capecitabine plus oxaliplatin.

The overall response rate (ORR) was the primary efficacy metric used in this study, which was examined by a blinded independent review committee. The ORR in the pembrolizumab arm was 74 percent (95 percent CI 66, 82) and in the placebo arm was 52 percent (95 percent CI 43, 61) (one-sided p-value 0.0001, statistically significant). The median duration of response (DoR) for participants treated with pembrolizumab was 10.6 months (range 1.1+, 16.5+) and 9.5 months (range 1.4+, 15.4+) for those in the placebo arm.

The adverse response profile reported in Study KEYNOTE-811 individuals receiving pembrolizumab matches the known pembrolizumab safety profile.

Adult patients with locally advanced unresectable or metastatic HER2 positive gastric or GEJ adenocarcinoma should take 200 mg every 3 weeks or 400 mg every 6 weeks of pembrolizumab in conjunction with trastuzumab and chemotherapy.

 

Reference : https://www.fda.gov/

Check details here.

 

Take second opinion on gastric cancer treatment


Send Details

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

PiggyBac Transposon System
AI & Technology

PiggyBac Transposon System: A Revolutionary Tool in Cancer Gene Therapy

The PiggyBac Transposon System is revolutionizing genetic engineering in cancer research, especially in CAR T-cell therapy. With its high integration efficiency and large cargo capacity, it provides a powerful, non-viral alternative to traditional gene delivery methods. Learn how PiggyBac is advancing personalized cancer treatment and shaping the future of oncology.

Breakthrough 2025 Treatments for Advanced Breast Cancer
Biotech Innovations

Breakthrough Treatments for Advanced Breast Cancer in 2025

In 2025, advanced breast cancer treatment has entered a new era. Precision medicine and targeted therapies are enabling doctors to tailor care based on genetic profiles. Immunotherapy and antibody-drug conjugates are delivering more effective tumor targeting, while experimental cellular treatments like CAR T-cell therapy show immense promise. These cutting-edge options are transforming outcomes and quality of life for patients facing metastatic breast cancer. Explore the latest innovations driving hope and progress.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

We Are Online! Chat With Us!
Scan the code